Filing Details

Accession Number:
0001181431-11-057717
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-11-28 16:49:25
Reporting Period:
2011-11-23
Filing Date:
2011-11-28
Accepted Time:
2011-11-28 16:49:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1484478 Furiex Pharmaceuticals Inc. FURX Pharmaceutical Preparations (2834) 271197863
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1033409 N Fredric Eshelman C/O Furiex Pharmaceuticals, Inc.
3900 Paramount Parkway, Suite 150
Morrisville NC 27560
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-11-23 15,278 $16.22 1,675,480 No 4 P Direct
Common Stock Acquisiton 2011-11-25 6,802 $16.00 1,682,282 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 41,666 Indirect GRAT
Common Stock 938 Indirect LLC
Common Stock 140 Indirect Spouse
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (to buy) $13.16 2021-10-03 98,813 98,813 Indirect
Common Stock Stock Options (to buy) $9.11 2020-06-17 197,627 197,627 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2021-10-03 98,813 98,813 Indirect
2020-06-17 197,627 197,627 Indirect
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $16.10 to $16.38. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
  2. The options were awarded on 10/3/2011 and vest over three years, with one-third of the options vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's employment continues.
  3. The options were awarded on 6/17/2010 and vest over three years, with one-third of the options vesting on each of the first, second and third anniversaries of the date of grant, provided the Optionee's consulting relationship continues.